Tag: alexion pharmaceuticals
March 11, 2020
Analyst Lowers BridgeBio Price Target After Debt Issuance
George Farmer told investors that BMO Capital Markets is lowering its price target for BridgeBio Pharma to US$46, down from... January 30, 2020
Alexion Reports Fourth Quarter and Full Year 2019 Results
Alexion Pharmaceuticals announced its financial results for the fourth quarter and its full fiscal 2019 year.
March 26, 2019
7 Potential Blockbuster Drugs Investors Should Watch for in 2019
A report by Cortellis says that seven drugs entering the market in 2019 are projected to reach blockbuster status by... September 24, 2018
Alexion Announces Successful Phase 3 PREVENT Study of Soliris (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder
Alexion Pharmaceuticals (NASDAQ:ALXN) today announced positive topline results from the Phase 3 PREVENT study of Soliris (eculizumab) in patients with anti-aquaporin-4 (AQP4)... June 28, 2018
Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria in the EU
Alexion Pharmaceuticals (NASDAQ:ALXN) announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for ALXN1210, the...
February 26, 2018
Positive Regulatory News from Two Pharmaceutical Companies Triggers Share Price Increases
Investors and analysts are focusing on KemPharm and Achillion after both companies received recent positive regulatory news. April 25, 2017